Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD
Status:
Completed
Trial end date:
2019-06-27
Target enrollment:
Participant gender:
Summary
Double-masked, uncontrolled, multi-center, study in which participants will be randomized to
one of 3 doses of topical ocular PAN 90806 administered once daily for 12 weeks.